CUE Stock Summary and Trading Ideas (Cue Biopharma | NASDAQ:CUE)

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Cue Biopharma trades on the NASDAQ stock market under the symbol CUE.

As of December 16, 2025, CUE stock price declined to $0.41 with 338,271 million shares trading.

CUE has a beta of 1.76, meaning it tends to be more sensitive to market movements. CUE has a correlation of 0.16 to the broad based SPY ETF.

CUE has a market cap of $32.28 million. This is considered a Sub-Micro Cap stock.

Last quarter Cue Biopharma reported $2 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-224,802 and exceeded earnings estimates by $.02.

In the last 3 years, CUE traded as high as $5.12 and as low as $.41.

The top ETF exchange traded funds that CUE belongs to (by Net Assets): VTI, VXF.

CUE has underperformed the market in the last year with a price return of -56.4% while the SPY ETF gained +13.6%. CUE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.6% and -31.1%, respectively, while the SPY returned +3.0% and -0.2%, respectively.

CUE support price is $.43 and resistance is $.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUE shares will trade within this expected range on the day.